Gero Kramer

8.5k total citations · 2 hit papers
185 papers, 5.0k citations indexed

About

Gero Kramer is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Gero Kramer has authored 185 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 129 papers in Pulmonary and Respiratory Medicine, 55 papers in Oncology and 47 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Gero Kramer's work include Prostate Cancer Treatment and Research (105 papers), Radiopharmaceutical Chemistry and Applications (43 papers) and Prostate Cancer Diagnosis and Treatment (32 papers). Gero Kramer is often cited by papers focused on Prostate Cancer Treatment and Research (105 papers), Radiopharmaceutical Chemistry and Applications (43 papers) and Prostate Cancer Diagnosis and Treatment (32 papers). Gero Kramer collaborates with scholars based in Austria, United States and Germany. Gero Kramer's co-authors include Michael Marberger, Georg Steiner, Dieter Mitteregger, Andrea Haitel, Shahrokh F. Shariat, Stephan Madersbacher, H. Christoph Klingler, Alessandra Handisurya, Fritz H. Schröder and Georg Schatzl and has published in prestigious journals such as New England Journal of Medicine, Circulation and Journal of Clinical Oncology.

In The Last Decade

Gero Kramer

172 papers receiving 4.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer

2019 377 citations Ronald de Wit, Johann S. de Bono et al. New England Journal of Medicine profile →
The Controversial Relationship Between Benign Prostatic Hyperplasia and Prostate Cancer: The Role of Inflammation

2011 346 citations Gero Kramer, Michael Marberger et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gero Kramer Austria	34	2.9k	1.1k	1.1k	886	852	185	5.0k
Juan Moróte Spain	37	2.8k 1.0×	1.1k 1.0×	1.1k 1.0×	526 0.6×	378 0.4×	358	4.8k
Sung Joon Hong South Korea	35	2.1k 0.7×	719 0.7×	761 0.7×	805 0.9×	360 0.4×	252	4.3k
Yoshiki Sugimura Japan	33	2.3k 0.8×	713 0.7×	2.0k 1.8×	692 0.8×	195 0.2×	193	5.1k
Masaru Murai Japan	44	2.7k 0.9×	1.3k 1.2×	2.4k 2.2×	299 0.3×	518 0.6×	234	6.5k
Satoru Kawakami Japan	40	2.2k 0.8×	985 0.9×	1.5k 1.4×	471 0.5×	598 0.7×	251	5.1k
Toshiyuki Kamoto Japan	37	1.6k 0.6×	840 0.8×	1.4k 1.3×	386 0.4×	168 0.2×	262	3.9k
Cheol Kwak South Korea	37	3.2k 1.1×	1.4k 1.3×	1.8k 1.7×	693 0.8×	490 0.6×	435	6.4k
Gabriella Nesi Italy	36	1.5k 0.5×	965 0.9×	977 0.9×	653 0.7×	151 0.2×	259	4.6k
Mitchell S. Steiner United States	42	2.9k 1.0×	1.1k 1.0×	1.7k 1.6×	1.1k 1.2×	137 0.2×	133	5.9k
Thomas Herrmann Germany	46	2.7k 1.0×	1.1k 1.0×	941 0.9×	2.4k 2.8×	232 0.3×	203	6.4k

Countries citing papers authored by Gero Kramer

Since Specialization

Citations

This map shows the geographic impact of Gero Kramer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gero Kramer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gero Kramer more than expected).

Fields of papers citing papers by Gero Kramer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gero Kramer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gero Kramer. The network helps show where Gero Kramer may publish in the future.

Co-authorship network of co-authors of Gero Kramer

This figure shows the co-authorship network connecting the top 25 collaborators of Gero Kramer. A scholar is included among the top collaborators of Gero Kramer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gero Kramer. Gero Kramer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mehra, Niven, Emmanuel S. Antonarakis, Se Hoon Park, et al.. (2025). Patient-reported Outcomes in KEYLYNK-010: Pembrolizumab Plus Olaparib Versus Abiraterone or Enzalutamide for Participants with Biomarker-unselected, Previously Treated Metastatic Castration-resistant Prostate Cancer. European Urology Oncology. 8(4). 1030–1040. 1 indexed citations

Spielvogel, Clemens P., Melanie R. Hassler, Lukas Nics, et al.. (2025). Does PARP1 up-regulation correlate with PSMA expression in patients with metastatic castration-resistant prostate cancer studied with [18F]PARPi and [68Ga]PSMA PET/CT?. European Journal of Nuclear Medicine and Molecular Imaging. 53(2). 812–823. 1 indexed citations

Reid, Alison, et al.. (2025). LBA6 Phase III trial of [177Lu]Lu-PSMA-617 combined with ADT + ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition). Annals of Oncology. 36. S1627–S1628. 1 indexed citations

Spielvogel, Clemens P., Gero Kramer, Bernhard Grubmüller, et al.. (2025). Imaging and outcome correlates of ctDNA methylation markers in prostate cancer: a comparative, cross-sectional [⁶⁸Ga]Ga-PSMA-11 PET/CT study. Clinical Epigenetics. 17(1). 36–36. 3 indexed citations

Nics, Lukas, Clemens P. Spielvogel, Bernhard Grubmüller, et al.. (2024). Assessment of PSMA Expression of Healthy Organs in Different Stages of Prostate Cancer Using [68Ga]Ga-PSMA-11-PET Examinations. Cancers. 16(8). 1514–1514. 2 indexed citations

Spielvogel, Clemens P., Gerda Egger, Gero Kramer, et al.. (2024). Comparison of discovery rates and prognostic utility of [68Ga]Ga-PSMA-11 PET/CT and circulating tumor DNA in prostate cancer—a cross-sectional study. European Journal of Nuclear Medicine and Molecular Imaging. 51(9). 2833–2842. 7 indexed citations

Klemm, Jakob, Markus von Deimling, Margit Fisch, et al.. (2023). Androgendeprivationstherapie und kardiovaskuläre Morbidität beim Prostatakarzinom: ein narratives Review. PubMed. 63(3). 262–268.

Petrylak, Daniel P., Raffaele Ratta, Nobuaki Matsubara, et al.. (2023). Patient-reported outcomes (PROs) in KEYNOTE-921: Pembrolizumab (pembro) plus docetaxel for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 41(6_suppl). 129–129. 1 indexed citations

Bono, Johann S. de, Neal D. Shore, Gero Kramer, et al.. (2021). 418 Phase 1b/2 KEYNOTE-365 cohort I: platinum-containing chemotherapy alone or in combination with pembrolizumab for treatment-emergent neuroendocrine prostate carcinoma. SHILAP Revista de lepidopterología. A448–A448. 2 indexed citations

10.

Petrylak, Daniel P., Raffaele Ratta, Rustem Gafanov, et al.. (2021). KEYNOTE-921: Phase III Study of Pembrolizumab Plus Docetaxel for Metastatic Castration-Resistant Prostate Cancer. Future Oncology. 17(25). 3291–3299. 32 indexed citations

11.

Marhold, Maximilian, Gero Kramer, Michael Krainer, & Clémentine Le Magnen. (2021). The prostate cancer landscape in Europe: Current challenges, future opportunities. Cancer Letters. 526. 304–310. 24 indexed citations

12.

Stangl‐Kremser, Judith, Sazan Rasul, Jeffrey J. Tosoian, et al.. (2021). Single-lesion Prostate-specific Membrane Antigen Protein Expression (PSMA) and Response to [177Lu]-PSMA-ligand Therapy in Patients with Castration-resistant Prostate Cancer. European Urology Open Science. 30. 63–66. 5 indexed citations

13.

Wit, Ronald de, Johann S. de Bono, Cora N. Sternberg, et al.. (2019). Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. New England Journal of Medicine. 381(26). 2506–2518. 377 indexed citations breakdown →

14.

Stangl‐Kremser, Judith, Ursula Lemberger, Melanie R. Hassler, et al.. (2019). Prevalence and Prognostic Value of the Polymorphic Variant 1245A>C of HSD3B1 in Castration-resistant Prostate Cancer. Clinical Genitourinary Cancer. 17(5). 389–394. 5 indexed citations

15.

Mitteregger, Dieter, Stephan W. Aberle, Athanasios Makristathis, et al.. (2011). High detection rate of Trichomonas vaginalis in benign hyperplastic prostatic tissue. Medical Microbiology and Immunology. 201(1). 113–116. 70 indexed citations

16.

Schmidinger, Manuela, Ursula Vogl, Marija Bojić, et al.. (2010). Hypothyroidism in patients with renal cell carcinoma. Cancer. 117(3). 534–544. 159 indexed citations

17.

Kramer, Gero, et al.. (2007). Chronische Inflammation als Promotor- und Behandlungstarget bei benigner Prostatahyperplasie (BPH) und beim Prostatakarzinom. Der Urologe. 46(9). 1095–1096. 2 indexed citations

18.

Herwig, Ralf, Bob Djavan, Gero Kramer, et al.. (2007). Prostatakarzinomscreening durch einen neuen Marker auf der Basis zirkulierender Blutmakrophagen?. Der Urologe. 46(9). 1066–1070. 1 indexed citations

19.

Kramer, Gero, Georg Steiner, Alessandra Handisurya, et al.. (2002). Increased expression of lymphocyte‐derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation. The Prostate. 52(1). 43–58. 164 indexed citations

20.

Kramer, Gero, Georg Steiner, Alessandra Handisurya, et al.. (2001). Local Intratumoral Tumor Necrosis Factor- α and Systemic IFN- α 2b in Patients with Locally Advanced Prostate Cancer. Journal of Interferon & Cytokine Research. 21(7). 475–484. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact